Product Images Duloxetine
View Photos of Packaging, Labels & Appearance
- Structure - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 01
- Figure 1 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 02
- Figure 2 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 03
- Figure 1 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 04
- Figure 2 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 05
- fig 5 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 06
- fig 6 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 07
- Fig 7 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 08
- Figure 8 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 09
- Figure 9 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 10
- Figure 10 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 11
- Image - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 935 1
- Image - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 942 1
- Label - lbl713352567
Product Label Images
The following 14 images provide visual information about the product associated with Duloxetine NDC 71335-2567 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Structure - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 01
Figure 1 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 02
This text provides information related to the proportion of patients with relapse in a study comparing placebo to duloxetine treatment over a specific time period (in days). The data is presented in a table or graph format, showing the outcomes for patients at different time points from randomization to relapse. The Kaplan-Meier estimator method is used for the analysis.*
Figure 2 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 03
This text provides data on the proportion of patients experiencing a relapse over time for both a placebo and duloxetine treatment. The information is presented in a table with the time from randomization to relapse in days. The data seems to have been analyzed using the Kaplan-Meier estimator method.*
Figure 1 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 04
This information appears to be presenting data regarding the percentage of patients who experienced improvement while taking different dosages of Duloxetine and Placebo. It mentions the percentage of patients improved with Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and Placebo. The table likely includes data on the percent improvement in pain from the baseline.*
Figure 2 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 05
Percentage of Patients Improved: R = 1 Percent Improvement in Pain from Baseline: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Placebo.*
fig 5 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 06
Percentage of Patients Improved with Duloxetine 60 mg Twice Daily, Duloxetine 60 mg Once Daily, and Placebo based on the different levels of pain improvement from the baseline. The chart shows the percentage of patients who experienced various levels of pain improvement, ranging from less than 10% to 100%.*
fig 6 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 07
This text provides information on the percentage of patients who experienced improvement in pain after taking different doses of Duloxetine and placebo. The data is represented in a table showing the level of improvement in increments from 10 to 100%. The highest improvement is seen with Duloxetine 120 mg taken twice daily.*
Fig 7 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 08
This text provides information on the percentage of pediatric patients aged 13 to 17 years old with Juvenile Fibromyalgia Syndrome achieving various levels of pain relief at week 12 in a study (FM-4). The study compares the effectiveness of Duloxetine 60mg once daily versus a placebo. The pain relief was measured using the Brief Pain Inventory - Modified Short Form: Adolescent Version Average Pain Score. Duloxetine-treated patients started with 30mg once daily for a week and then titrated to 60mg once daily for 12 weeks.*
Figure 8 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 09
This data represents the percentage of patients improved with Duloxetine 60/120 mg once daily compared to a Placebo, as per the Percent Improvement in Pain from Baseline analysis. The chart ranges from 0 to 100, showing the level of improvement in pain reported by patients.*
Figure 9 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 10
This is a chart displaying the percentage of patients improved with Duloxetine 60 mg compared to a placebo. The improvement is measured on a scale showing percentage improvement in pain from baseline. The chart indicates that 100% of patients experienced improvement when taking Duloxetine 60 mg once daily.*
Figure 10 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 11
This text provides information on the percentage of patients improved in a study comparing a placebo to Duloxetine at 60/120 mg dosage. It includes a chart showing the percentage improvement in pain from baseline. The data indicates that the Duloxetine treatment showed significant improvement compared to the placebo.*
Image - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 935 1
Image - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 942 1
Label - lbl713352567
This text is a description of medication containing Duloxetine Hydrochloride in delayed-release capsules. It provides information on the dosage, storage conditions, manufacturer details, and instructions for pharmacists on dispensing the medication. It also mentions the National Drug Code (NDC) for the product. Make sure to check the package insert QR code for detailed dosage information.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
